ThermoGenesis Holdings Inc. (THMO) - Likuiditas cepet

ThermoGenesis (THMO) business relies on the demand for PXP systems for stem cell research and the sale of associated consumables. This price chart illustrates the asset's dynamics, where the current coefficient is 0.37. Unique patents and strict FDA regulations ensure the protection of its niche. Stable cash flow is generated through the sale of cryogenic units and the maintenance of biobanks.

The quick ratio measures a company's ability to meet short-term obligations using its most liquid assets, intentionally excluding slow-moving inventories. For ThermoGenesis (THMO), whose laboratory trust is built on high-tech bioengineering, this filter separates actual cash flow from the value of equipment in warehouses. The trend of the quick ratio reflects the efficiency of working capital management. Stable values confirm the financial autonomy and resilience of the business against sudden market shocks.